ERBF at the ASBMR 2025 Annual Meeting in Seattle
ERBF at the ASBMR 2025 Annual Meeting in Seattle to present a poster on Research and Development of Treatments for Rare Bone Conditions.
ERBF at the ASBMR 2025 Annual Meeting in Seattle Read More »
ERBF at the ASBMR 2025 Annual Meeting in Seattle to present a poster on Research and Development of Treatments for Rare Bone Conditions.
ERBF at the ASBMR 2025 Annual Meeting in Seattle Read More »
White Paper Published: Mapping the Future of R&D for Rare Bone Conditions in Europe. Research & Development of Treatments for Rare Bone Conditions in Europe, developed in collaboration with Costello Medical.
White Paper Published: Mapping the Future of R&D for Rare Bone Conditions in Europe Read More »
Rare Bone Diseases (RBDs) represent a heterogeneous group of 771 rare conditions of genetic origin that affect the development, growth, and structure of bones and cartilage, causing short stature and abnormalities of the limbs, extremities, and spine. A recently published article called Improving care pathways for people living with rare bone diseases intends to outline the priorities for people with these conditions.
ERBF to Present White Paper at ESPE-ESE Joint Congress 2025 Read More »
Rare Bone Diseases (RBDs) represent a heterogeneous group of 771 rare conditions of genetic origin that affect the development, growth, and structure of bones and cartilage, causing short stature and abnormalities of the limbs, extremities, and spine. A recently published article called Improving care pathways for people living with rare bone diseases intends to outline the priorities for people with these conditions.
Improving care pathways for people living with rare bone diseases Read More »
We will be participating in the ECTS Congress 2023 in Liverpool. We will be moderating an ECTS-ISCBH Workshop on April 14.
ECTS-ISCBH workshop in conjunction with the European Rare Bone Forum Read More »
We are pleased to announce that we will be participating in the ECTS Congress 2022 in Helsinki. We will sponsor an Education Symposium and the European Rare Bone Forum General Meeting will also take place during the event.
ERBF Education Symposium and General Meeting at ECTS 2022 Read More »
On Jan 24, Ipsen announced the Canada approval of Sohonos (palovarotene). Indicated to reduce new bone formation in adults and children with FOP. Sohonos is approved for both chronic use, and for flare-ups. It is the first approval for Sohonos worldwide.
Canada Approves Palovarotene treatment for FOP Read More »
The European Rare Bone Forum, requested a proposal from Costello Medical to assist in a call to action to shorten the time between research and clinical care.
The CALL TO ACTION project Read More »
Please join us on Thursday October 29, 2020 15h CET. Julia Quitmann (University Medical Center, Hamburg – Eppendorf) will be our Speaker addressing Quality of Life Studies in Rare Bone Diseases: why, who and how? This Webinar has the support of the European Calcified Tissue Society (ECTS).
QoL Studies in Rare Bone Diseases: why, who & how? Read More »